Featured Story

Sanofi looking for big efficiency gains at French plants

Sanofi's new CEO, Olivier Brandicourt, warned union workers in June that for the company to grow its French manufacturing operations, they needed to get more efficient, but he didn't say by how much. They need to improve a lot, it turns out.

Hospira manufacturing mess-up leads to PharMEDium recalls

Hospira recalled 661,000 bags of sodium chloride at the first of the year after a customer discovered a human hair in the additive port area of a bag. That recall has now bled into products of a Hospira client that used some of the solution to compound a bunch of drugs for its customers.

Cipla moves forward with deal for plant in Algeria

India's Cipla has said in a filing with the Bombay Stock Exchange that it has completed a move forward with a joint venture in Algeria that will lead to the production of respiratory drugs there.

Pfizer finds buyer for Indian plant set to close this month

Pfizer said two months ago that it would close a 55-year-old plant in Thane, India, that it no longer wanted. But someone sees some value in it, and the U.S. drugmaker now says the facility will be sold to an Indian operation for nearly $27 million.

Baxter recalls more saline, this time for potential mold contamination

The U.S. supply of saline is taking another hit as Baxter recalls yet more sodium chloride: nearly 140,000 bags more. This time the recall is because of the possibility that some of those bags have mold in them.


From Our Sister Sites


When the FDA last year yanked away its initial approval of Ranbaxy's generics of two blockbusters including the heartburn med Nexium, the Indian drugmaker fired back with a lawsuit against the FDA. But Ranbaxy is now owned by Sun Pharmaceutical, which sees no upside to fighting with the agency, and so it has dropped the litigation.


Credit Suisse analyst Vamil Divan is optimistic about sales of Eli Lilly and Boehringer Ingelheim's Jardiance. He's raised his rating on Lilly to outperform, lifting his stock price target to $105--25% above Thursday's closing price of $83.77.